614 reports of this reaction
5.6% of all EPIRUBICIN HYDROCHLORIDE reports
#1 most reported adverse reaction
MYELOSUPPRESSION is the #1 most commonly reported adverse reaction for EPIRUBICIN HYDROCHLORIDE, manufactured by Pharmacia & Upjohn Company LLC. There are 614 FDA adverse event reports linking EPIRUBICIN HYDROCHLORIDE to MYELOSUPPRESSION. This represents approximately 5.6% of all 10,973 adverse event reports for this drug.
Patients taking EPIRUBICIN HYDROCHLORIDE who experience myelosuppression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYELOSUPPRESSION is moderately reported among EPIRUBICIN HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to myelosuppression, the following adverse reactions have been reported for EPIRUBICIN HYDROCHLORIDE:
The following drugs have also been linked to myelosuppression in FDA adverse event reports:
MYELOSUPPRESSION has been reported as an adverse event in 614 FDA reports for EPIRUBICIN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYELOSUPPRESSION accounts for approximately 5.6% of all adverse event reports for EPIRUBICIN HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience myelosuppression while taking EPIRUBICIN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.